Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.
Using Long-Acting Injectable Buprenorphine as a Means to Discontinue Medication for Addiction Treatment of Opiate Use Disorder
Presented by Jeff Ripperda, MD, Family Physician, Co-Founder of Shawnee Health's Substance Use Disorder Program
This case series describes the experiences of sixteen patients with a history of opiate use disorder who had been stable on buprenorphine treatment, but who expressed a desire to discontinue medication for addiction therapy. These patients received variable dosages and durations of long-acting injectable buprenorphine. At least ten of the patients successfully discontinued medication for addiction treatment.
Learning objectives:
After the presentation, attendees will be able to:
Identify patients who are potential candidates for discontinuation of medication for addiction treatment.
Identify a potential medication protocol for cessation of medication for addiction treatment.
This CME activity meets Illinois state requirements for safe opioid prescribing and federal training requirements for opioid safety.
We have applied for Continuing Medical Education (CME) credit through the American Academy of Family Physicians (AAFP). CME approval is contingent upon review by the AAFP. Additional details regarding available CME credit and the number of credit hours will be announced after approval is received.
Questions? Contact us at education@iafp.com